Bayer's 7-2 Supreme Court Win Sets Up a High-Stakes July 9 Hearing — and a Debt Problem That Won't Go Away

The U.S. Supreme Court handed Bayer a decisive legal victory on June 25, 2026, ruling 7-2 to toss out a multi-million-dollar judgment against the German conglomerate over its Roundup herbicide. The stock responded in kind, surging nearly 19% in the past week and more than 77% over the trailing twelve months, yet the rally shows signs of overheating. The shares currently trade around €45.50, still more than 8% below their 52-week high of €49.93, and the relative strength index sits at 73.8 — a level that typically signals overbought conditions. The euphoria may be real, but the next hard catalyst arrives on July 9, when a Missouri court weighs final approval of a proposed multibillion-dollar settlement.

That pending hearing is the true inflection point. The Supreme Court ruling does not extinguish the roughly 10,000 remaining glyphosate claims; it merely removes the most damaging precedent. Bayer has already agreed to a comprehensive settlement worth up to $7.25 billion, but the deal requires judicial sign-off. Plaintiffs' attorneys have voiced objections, and CEO Bill Anderson has hinted that if permanent legal certainty is not achieved, the company may exit U.S. glyphosate production altogether. Adding to the uncertainty, a separate U.S. trade investigation into German drug pricing has been launched, threatening to impose new tariffs or pricing pressure on Bayer's pharmaceutical business — a risk the market has so far largely ignored.

Beyond glyphosate, the legal calendar remains crowded. Bayer is locked in a simmering dispute with Johnson & Johnson over competing prostate-cancer drugs. The company accuses J&J of making false superiority claims about its drug Erleada over Bayer's Nubeqa. A federal judge in Manhattan refused to grant a preliminary injunction in April, prompting Bayer to file an amended complaint in June seeking permanent injunctive relief and damages. Meanwhile, the company continues to invest in next-generation research through a partnership with Iambic Therapeutics, an AI-driven drug-discovery firm whose platforms Enchant and NeuralPLexer are being deployed to identify novel targets and molecules. Bayer also closed the acquisition of Perfuse Therapeutics in June, adding an ophthalmology pipeline. On the development front, Nubeqa and Kerendia are delivering strong sales growth, and positive Phase III data for the stroke-prevention candidate Asundexian — released in February — bolsters the mid-term revenue outlook.

Should investors sell immediately? Or is it worth buying Bayer?

The structural relief from the Supreme Court cannot, however, mask the burden of Bayer's balance sheet. Net debt stood at €32.5 billion at the end of the first quarter, and the company expects it to rise to as much as €33 billion by year-end. Litigation costs for 2026 are estimated at roughly €5 billion, with around €2 billion already paid out in the first quarter alone for PCB and glyphosate settlements. That reverses the progress made in 2025, when free cash flow of €2.1 billion helped trim net debt from €32.6 billion to €29.8 billion. The math is simple: as long as cash outflows for legal settlements drain the coffers, the path to deleveraging remains blocked. Anderson's internal efficiency drive — aimed at cutting bureaucracy and streamlining operations — is designed to boost margins, but it will take time to offset the cash drag.

The July 9 settlement hearing is the single most important near-term trigger. If the court approves the deal, the glyphosate overhang will largely evaporate, freeing management to focus on operations and debt reduction. If the hearing is postponed or the deal rejected, the uncertainty will resurface with force, and the recent rally will face a serious test. Beyond that date, two questions will dominate: whether the company can stabilize net debt in the coming quarters, and whether management is prepared to offer investors any flexibility on the conglomerate structure — even without a full breakup. A meaningful signal in either direction could shift sentiment. For now, Bayer has bought itself time, but the meter is still running.

Ad

Bayer Stock: New Analysis - 30 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYERS | boerse | 69656596 |